

# Programme Overview

ROOM: SILVER	RED	BLUE	YELLOW
<b>Wednesday 20 March</b>			
<b>Opening Ceremony. Arts &amp; Humanities Award &amp; Clinical Science Award</b> <i>08:00-09:00</i>			
<b>Clinical Symposium</b> Immunotherapy beyond PD1/PDL1 checkpoint inhibitors and newer Antibody-drug-conjugates: the basics and the future <i>09:00-10:30</i>			
<b>Coffee Break (free of charge) / Poster in the Spotlight in Exhibition Hall   10:30-11:00</b>			
<b>Young Investigator Innovation Award and Oral abstracts</b> <i>11:00-12:55</i>		<b>Europa Donna session</b> Can we reduce breast cancer risk? <i>11:30-12:30</i>	
<b>Cashbar lunch in Exhibition Hall / Poster Area   12:30-14:00</b>			
<b>Plenary Session</b> Keynote <i>14:00-14:30</i>			
<b>Debate</b> HER2 Low <i>14:45-15:45</i>	<b>Society Session</b> European Society of Surgical Oncology (ESSO): Controversies in breast cancer surgery <i>14:45-15:45</i>	<b>Society Session</b> European Society of Pathology (ESP): Biomarkers in breast cancers and biological perspectives <i>14:45-15:45</i>	
<b>Coffee Break (free of charge) / Industry Forum in Exhibition Hall   15:45-16:15</b>			
<b>Clinical Symposium</b> Invasive lobular breast cancer (ILC) <i>16:15-17:45</i>	<b>Clinical Symposium</b> Towards second generation early detection of breast cancer <i>16:15-17:45</i>		

**Welcome reception in Exhibition Hall | 17:45-19:00**

Programme subject to change. For the latest visit [www.eortc.org/ebcc](http://www.eortc.org/ebcc)

ROOM: SILVER	RED	BLUE	YELLOW
<b>Thursday 21 March</b>			
<b>Clinical Symposium</b> Treatment of HR+ HER2- ABC: current standard of care & perspectives <b>08:00-09:30</b>		<b>Young Investigator Session</b> Clinical and Translational Breast Cancer Research: Navigating Challenges and Unlocking Potential for Young Investigators <b>09:00-10:00</b>	
<b>Young Investigator Innovation Award and Oral abstracts</b> <b>09:30-10:55</b>	<b>Europa Donna session</b> Equal access to innovation in breast cancer treatment <b>10:00-11:00</b>		<b>Society Session</b> European Society of Breast Imaging (EUSOBI): Towards image guided modulation of breast cancer therapy. <b>10:00-11:00</b>
<b>Coffee Break (free of charge) / Poster in the Spotlight in Exhibition Hall   11:00-11:30</b>			
<b>Debate</b> This house believes that doing more surgery to get access to new adjuvant therapies among which CDK4/6-inhibitors is a backward step <b>11:30-12:30</b>	<b>Society Session</b> European Society of Breast Cancer Specialists (EUSOMA): The multidisciplinary meeting (MDM) in a Breast Centre: a real-life case discussion <b>11:30-12:30</b>	<b>Group Session</b> Early Breast Cancer Trialists' Collaborative Group (EBCTCG) - Progress Report <b>11:30-12:30</b>	<b>Society Session</b> European Association for Cancer Research (EACR): Breast cancer progression: new approaches to answer long-standing questions <b>11:30-12:30</b>
<b>Debate</b> Every woman deserves to know her own genetic risk to get breast cancer <b>12:30-13:00</b>			
<b>Cashbar lunch in Exhibition Hall / Poster Area   12:30-14:00</b>			
<b>Debate</b> This house believes that pembrolizumab needs to be continued as post-neoadjuvant treatment in patients with TNBC disease <b>14:00-15:00</b>	<b>Multidisciplinary Team in the Real World</b> Management of individuals with breast cancer germline susceptibility <b>14:00-15:00</b>		<b>Society Session</b> European Society for Radiotherapy & Oncology (ESTRO): Early Breast Cancer Radiation Therapy Challenges in the Oncoplastic Era <b>14:00-15:00</b>
<b>Clinical Symposium</b> Can real world data replace the traditional control arm in a trial? <b>15:15-16:45</b>	<b>Clinical Symposium</b> Lifestyle interventions to improve quality of care after breast cancer <b>15:15-16:45</b>		
<b>Coffee Break (free of charge) / Industry Forum in Exhibition Hall   16:45-17:15</b>			
<b>Multidisciplinary Team in the Real World</b> Management of the old frail patient <b>17:15-18:15</b>	<b>Best Practice</b> What survivorship means for breast cancer patients & physicians <b>17:15-18:15</b>		

ROOM: SILVER	RED	BLUE	YELLOW
<b>Friday 22 March</b>			
<b>Clinical Symposium</b> De-escalation of axillary therapy after upfront surgery and after primary systemic therapy <b>08:00-09:30</b>	<b>Clinical Symposium</b> Brain metastases <b>08:00-09:30</b>		
<b>Oral abstracts session</b> <b>09:30-11:15</b>			<b>Europa Donna session</b> I want to be able to work, if I can <b>10:00-11:00</b>
<b>Coffee Break (free of charge) / Poster in the Spotlight in Exhibition Hall   11:00-11:30</b>			
<b>Debate</b> Adjuvant CDK4/6-inhibitors <b>11:30-12:30</b>	<b>Debate</b> This house believes that a second breast conserving surgery should always be performed in case of small recurrence early disease <b>11:30-12:30</b>		<b>Best practice</b> Breast reconstruction and radiation therapy <b>11:30-12:30</b>
<b>Cashbar lunch in Exhibition Hall / Poster Area   12:30-14:00</b>			
<b>Manifesto Session</b> Addressing disparities in access to innovation for patients with metastatic breast cancer across Europe <b>14:00-15:10</b>			
<b>Closing Session</b> Keynote <b>15:10-15:40</b>			